Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014

S A McNeil; V Shinde; M Andrew; T F Hatchette; J LeBlanc; A Ambrose; G Boivin; W R Bowie; F Diaz-Mitoma; M ElSherif; K Green; F Haguinet; S Halperin; B Ibarguchi; K Katz; JM Langley; P Lagacé-Wiens; B Light; M Loeb; J E McElhaney; D MacKinnon-Cameron; A E McCarthy; M Poirier; J Powis; D Richardson; M Semret; S Smith; D Smyth; G Stiver; S Trottier; L Valiquette; D Webster; L Ye; A McGeer; on behalf of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network; on behalf of the Toronto Invasive Bacterial Diseases Network (TIBDN)

doi:10.2807/1560-7917.ES2014.19.9.20729

Rapid communications Open Access

Like 0

Download

Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014
S A McNeil¹ , V Shinde² , M Andrew¹ , T F Hatchette¹ , J LeBlanc¹ , A Ambrose¹ , G Boivin³ , W R Bowie⁴ , F Diaz-Mitoma⁵ , M ElSherif¹ , K Green⁶ , F Haguinet² , S Halperin¹ , B Ibarguchi⁷ , K Katz⁸ , JM Langley¹ , P Lagacé-Wiens⁹ , B Light⁹ , M Loeb¹⁰ , J E McElhaney⁵ , D MacKinnon-Cameron¹ , A E McCarthy¹¹ , M Poirier¹² , J Powis¹³ , D Richardson¹⁴ , M Semret¹⁵ , S Smith¹⁶ , D Smyth¹⁷ , G Stiver⁴ , S Trottier³ , L Valiquette¹⁸ , D Webster¹⁹ , L Ye¹ , A McGeer⁶ , on behalf of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network²⁰ , on behalf of the Toronto Invasive Bacterial Diseases Network (TIBDN)²¹
View Affiliations Hide Affiliations

Affiliations: ¹ Canadian Center for Vaccinology, IWK Health Centre and Capital Health, Dalhousie University, Halifax, Nova Scotia, Canada ² GlaxoSmithKline Biologicals, Wavre, Belgium ³ CHU de Québec, Quebec, Canada ⁴ University of British Columbia, Vancouver, British Columbia, Canada ⁵ Advanced Medical Research Institute of Canada, Sudbury, Ontario, Canada ⁶ Mount Sinai Hospital, Toronto, Ontario, Canada ⁷ GlaxoSmithKline, Mississauga, Ontario, Canada ⁸ North York General Hospital, Toronto, Ontario, Canada ⁹ St. Boniface Hospital, Winnipeg, Manitoba, Canada ¹⁰ McMaster University, Hamilton, Ontario, Canada ¹¹ The Ottawa Hospital, Ottawa, Ontario, Canada ¹² Centre de santé et de service sociaux de Trois-Rivieres, Trois-Rivieres, Quebec, Canada ¹³ Toronto East General Hospital, Toronto, Ontario, Canada ¹⁴ William Osler Health Centre, Brampton, Ontario, Canada ¹⁵ McGill University, Montreal, Quebec, Canada ¹⁶ University of Alberta, Edmonton, Alberta, Canada ¹⁷ The Moncton Hospital, Moncton, New Brunswick, Canada ¹⁸ Université de Sherbrooke, Sherbrooke, Quebec, Canada ¹⁹ Horizon Health, Saint John, New Brunswick, Canada ²⁰ www.pcirn.ca ²¹ www.tibdn.ca

Correspondence:
S McNeil
shelly.mcneil cdha.nshealth.ca
View Citation Hide Citation

Citation style for this article: McNeil S A, Shinde V, Andrew M, Hatchette T F, LeBlanc J, Ambrose A, Boivin G, Bowie W R, Diaz-Mitoma F, ElSherif M, Green K, Haguinet F, Halperin S, Ibarguchi B, Katz K, Langley JM, Lagacé-Wiens P, Light B, Loeb M, McElhaney J E, MacKinnon-Cameron D, McCarthy A E, Poirier M, Powis J, Richardson D, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, Ye L, McGeer A, on behalf of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network, on behalf of the Toronto Invasive Bacterial Diseases Network (TIBDN). Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill. 2014;19(9):pii=20729. https://doi.org/10.2807/1560-7917.ES2014.19.9.20729 Received: 24 Feb 2014

Abstract

During the 2013/14 influenza season in Canada, 631 of 654 hospitalisations for laboratory-confirmed influenza enrolled in sentinel hospitals were due to Influenza A. Of the 375 with known subtype, influenza A(H1N1) accounted for 357. Interim unmatched vaccine effectiveness adjusted for age and presence of one or more medical comorbidities was determined by test-negative case-control design to be 58.5% (90% confidence interval (CI): 43.9-69.3%) overall and 57.9% (90% CI: 37.7-71.5) for confirmed influenza A(H1N1). .